Back to first-pass browser

First-pass extracted concept

clozapine-N-oxide

Candidate: toolkit item2 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Aliases

CNO

Extracted Explainers

What the tool is doing

CNO is the designer drug applied to increase activity in neurons expressing hM3Dq DREADD in this study.

Source 1DOIPubMed

CNO is presented as a DREADD actuator used for remote control of targeted cell populations through modified receptors. In this paper, it also altered sleep in wild-type mice lacking DREADD receptors.

Source 2DOIPubMed

Resources required

Its use depends on prior delivery and expression of the hM3Dq chemogenetic construct.

Source 1DOIPubMed

Use requires a chemogenetic experiment with actuator administration; the abstract specifically reports intraperitoneal injection and sleep analysis by EEG and EMG in mice.

Source 2DOIPubMed

What problem it solves

It allows the investigators to induce tonic excitation of the targeted afferent population during treadmill training.

Source 1DOIPubMed

It serves as a chemical input for DREADD-based control of targeted cell populations.

Source 2DOIPubMed

What it does not solve

It does not provide biologically inert actuation, because the abstract reports sleep modulation in mice not expressing DREADD receptors.

Source 2DOIPubMed

Alternatives

The abstract does not name an alternative agonist; it contrasts the chemogenetic strategy more broadly with epidural electrical stimulation.

Source 1DOIPubMed

The abstract contrasts CNO with compound 21 as a newer DREADD actuator and discusses clozapine as a mechanistic comparator for some observed effects.

Source 2DOIPubMed

Evidence Snippets

application of the designer drug Clozapine-N-oxide (CNO), inducing tonic excitation during treadmill training in the recovery phase
Evidence 1Source 1DOIPubMedprovenance
the DREADD actuator clozapine-N-oxide (CNO)
Evidence 2Source 2DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1negative resultsupports2025Source 1DOIPubMed

Withdrawal of DREADDs activation in week seven did not cause significant changes in kinematics, suggesting diminished late-stage effects.

Quoted textsource-backed
withdrawal of DREADDs activation in week seven did not cause significant changes in kinematics, suggesting that activation may have dwindling effects at this later stage.
Claim 2experimental recommendationsupports2023Source 2DOIPubMed

Chemogenetic experiments should include a DREADD-free control group injected with the same actuator.

Quoted textsource-backed
Therefore, any chemogenetic experiment should include a DREADD-free control group injected with the same CNO, C21, or newly developed actuator.
Claim 3mechanistic hypothesissupports2023Source 2DOIPubMed

The sleep effects of CNO could arise from back-metabolism to clozapine or binding to endogenous neurotransmitter receptors.

Quoted textsource-backed
Effects of CNO on sleep could arise from back-metabolism to clozapine or binding to endogenous neurotransmitter receptors.
Claim 4mechanistic inferencesupports2023Source 2DOIPubMed

Back-metabolism to clozapine is not the sole mechanism underlying side effects of chemogenetic actuators.

Quoted textsource-backed
This implies that back-metabolism to clozapine is not the sole mechanism underlying side effects of chemogenetic actuators.
Claim 5off target effectsupports2023Source 2DOIPubMed

Intraperitoneal CNO at commonly used doses alters sleep in wild-type male laboratory mice.

Quoted textsource-backed
Here, we show that intraperitoneal injections of commonly used CNO doses (1, 5, and 10 mg/kg) alter sleep in wild-type male laboratory mice.
Claim 6phenotype effectsupports2023Source 2DOIPubMed

CNO causes dose-dependent suppression of REM sleep, changes in NREM EEG spectral power, and altered sleep architecture in wild-type male laboratory mice.

Quoted textsource-backed
Using electroencephalography (EEG) and electromyography (EMG) to analyse sleep, we found a dose-dependent suppression of rapid eye movement (REM) sleep, changes in EEG spectral power during non-REM (NREM) sleep, and altered sleep architecture in a pattern previously reported for clozapine.